ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cohort Study"

  • Abstract Number: 2698 • ACR Convergence 2025

    Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study

    Yun Kyu Kim1, Hajeong Lee2, Jun Won Park3, Eun Bong Lee3, You-Jung Ha4 and Jin Kyun Park2, 1Seoul National University, Seoul, Republic of Korea, 2Seoul National University Hospital, Seoul, Republic of Korea, 3Seoul National University Hospital, Seoul, South Korea, 4Seoul National University Bundang Hospital, Seongnam, South Korea

    Background/Purpose: The efficacy of calcineurin inhibitors in the induction treatment of lupus nephritis (LN) has been increasingly supported by recent studies. Based on these findings,…
  • Abstract Number: 0209 • ACR Convergence 2025

    A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients

    Yuanteng Li1, Cheuk Leung2, Heather Lin2, Angeles Lopez-Olivio3 and Jean Tayar3, 1MD Anderson Cancer Center, Houston, TX, 2MD Anderson Cancer Center, Houston, 3The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Arthrocentesis and joint injections are commonly performed to diagnose and to treat rheumatic conditions such as crystal-induced arthritis, septic arthritis, and inflammatory arthritis. While…
  • Abstract Number: 0453 • ACR Convergence 2025

    Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD

    kyung-Ann Lee1, Bora Lee2, Hyun-Sook Kim3 and Se Hee Kim4, 1Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, 2Chosun University, GwangJu, Republic of Korea, 3Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, 4Kyung Hee University College of Medicine, Seoul, Republic of Korea

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening extra-articular manifestation of RA. The comparative safety of disease-modifying antirheumatic drugs (DMARDs) in RA…
  • Abstract Number: 0609 • ACR Convergence 2025

    Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes

    Eleni Papachristodoulou1 and Vasileios Kyttaris2, 1Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, 2Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

    Background/Purpose: Neutropenia is a known hematologic manifestation of SLE, yet its clinical implications remain poorly defined. We conducted a retrospective study to characterize the frequency,…
  • Abstract Number: 1125 • ACR Convergence 2025

    Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout

    Brian Coburn1, Daniel Wright2, Jeff Newcomb3, Mary Brophy4, Anne Davis-Karim5, Ryan Ferguson4, Michael Pillinger6, Tuhina Neogi7, Paul Palevsky8, Bryant England3, James O'Dell3, Lisa Stamp9, Ted Mikuls3 and Joshua Baker10, 1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Otago, Dunedin, New Zealand, 3University of Nebraska Medical Center, Omaha, NE, 4VA Cooperative Studies Program Coordinating Center, Boston, MA, 5VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, 6New York University Grossman School of Medicine, New York,, NY, 7Boston University School of Medicine, Boston, MA, 8VA Pittsburgh Healthcare System, Pittsburgh, PA, 9University of Otago, Christchurch, Christchurch, New Zealand, 10University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Despite evidence-based recommendations, allopurinol dose escalation to goal serum urate (SU) is frequently suboptimal. The EasyAllo tool was developed to facilitate pre-planned allopurinol dose…
  • Abstract Number: 1429 • ACR Convergence 2025

    Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer

    Savannah Bowman1, Mei Li2, Xiudong Lei3, Hui Zhao3, Juan Ruiz4, Sharon H. Giordano3, Alexis Ogdie5 and Maria Suarez-Almazor6, 1Baylor College of Medicine, Houston, 2The University of Texas Health Science Center at Houston, Houston, 3The University of Texas MD Anderson Cancer Center, Houston, 4Hospital Alemán, Buenos Aires, Argentina, 5University of Pennsylvania, Philadelphia, PA, 6MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Axial spondyloarthritis (axSpA) is associated with several comorbidities, including cancer. Prior studies have shown that elderly patients with rheumatoid arthritis and concomitant breast or…
  • Abstract Number: 1631 • ACR Convergence 2025

    New Arterial Damage in Takayasu’s Arteritis

    Tanaz Kermani1, Sema Kaymaz-Tahra2, Aysegul Avcu3, Fatma Alibaz-Oner4, Haner Direskeneli3 and Peter Merkel5, 1University of California Los Angeles, Santa Monica, CA, 2Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, 3Marmara University, Istanbul, Turkey, 4MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY, Istanbul, Turkey, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Damage is one of the consequences of disease and is often considered irreversible. This study aimed to evaluate new arterial damage in Takayasu’s arteritis…
  • Abstract Number: 1960 • ACR Convergence 2025

    Item Response Theory to Develop an Ultrasound Composite Score for Knee Osteoarthritis Assessment

    Liubov Arbeeva1, Carolina Alvarez2, Jonathan Samuels3, Janice Lin4, Minna Kohler5, Catherine Bakewell6, Todd Schwartz7 and Amanda Nelson8, 1University of North Carolina, Chapel Hill, Carrboro, NC, 2University of North Carolina at Chapel Hill, Miami, FL, 3NYU Langone, Rye Brook, NY, 4Stanford University, Palo Alto, CA, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, 6Intermountain Healthcare, Salt Lake City, UT, 7University of North Carolina-Chapel Hill, Chapel Hill, NC, 8University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Semi-quantitative scoring systems have long been used for radiographic findings in osteoarthritis (OA), but limited work has utilized ultrasound (US). The aim of this…
  • Abstract Number: 2118 • ACR Convergence 2025

    Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study

    Grace Hyeyeon Lee1, Hamzah Amin2 and marwan Bukhari1, 1University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom, 2Lancaster University, Lancaster, United Kingdom

    Background/Purpose: Anticonvulsants are commonly used to manage neurological and psychiatric disorders such as epilepsy, migraines and bipolar disorder. These medications are often prescribed long-term, and…
  • Abstract Number: 2453 • ACR Convergence 2025

    Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE

    Maral DerSarkissian1, Yan Chen1, Ariel Chao1, Shumin Rui1, Bronwyn Moore2, Karen Worley3, Daniel Moldaver4, Jeffrey J. Ellis3 and Aarat M Patel5, 1Analysis Group, Los Angeles, CA, 2Analysis Group, Montreal, QC, Canada, 3GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, 4GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, 5GSK, US Medical Affairs, Durham, NC

    Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…
  • Abstract Number: 2703 • ACR Convergence 2025

    Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis

    Ruoheng Zeng1, Ryan Rebello2, Konstanze Guggenberger3, Joshua Baker4, Shubhasree Banerjee4, Robert Kurtz4, Naomi Amudala4, Peter Merkel4 and Rennie Rhee4, 1University of Pennsylvania School of Medicine, Philadelphia, PA, 2St. Joseph’s Hospital at McMaster University, Hamilton, ON, Canada, 3University Hospital of Wuerzburg, Wuerzburg, Germany, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…
  • Abstract Number: 0223 • ACR Convergence 2025

    Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic

    Gopisree Peringeth1, Benedict Wu1, Shudan Wang2, Beth McLellan3, Clement Tagoe4 and Jeanie Lee1, 1Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, 4Albert Einstein College of Medicine, FRESH MEADOWS, NY

    Background/Purpose: Collagen vascular diseases (CVD) often present with skin manifestations, but it is not always clear whether these changes are directly related to the underlying…
  • Abstract Number: 0481 • ACR Convergence 2025

    Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study

    Chandrashekara MN1, AASTHA KHULLAR2, Bidyalaxmi Leishangthem3, Shankar Naidu4, Varun Dhir5 and Sanjay Jain4, 1PGIMER, Chandigarh, Chandigarh, India, 2Postgraduate Institute of Medical Education and Research, CHANDIGARH, Chandigarh, India, 3PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, 4Post graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, Chandigarh, India, 5PGIMER, CHD, INDIA, CHANDIGARH, Chandigarh, India

    Background/Purpose: Methotrexate (MTX) polyglutamates (MTX-PGs), the intracellular active forms of MTX, are hypothesized to reflect cumulative exposure and potentially predict therapeutic efficacy in rheumatoid arthritis…
  • Abstract Number: 0611 • ACR Convergence 2025

    Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study

    Fadi Kharouf1, Pankti Mehta2, Qixuan Li2, Dafna D. Gladman3, Laura Whitall Garcia4 and Zahi Touma5, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

    Background/Purpose: Venous thromboembolism (VTE) is a known complication of systemic lupus erythematosus (SLE), yet there is a lack of high-quality studies specifically focused on lupus…
  • Abstract Number: 1146 • ACR Convergence 2025

    Association of Walking Volume and Intensity With Incident Gout: A Population-based Cohort Study

    Ziying Wu1, Ying Hu2, Hongyi He3, Yuqing Zhang4, Nicola Dalbeth5, Junqing xie6, Yilun Wang7, Chao Zeng7, Guanghua Lei7 and Jie Wei7, 1Xiangya Hospital, Central South University, Chang Sha, China (People's Republic), 2Xiangya School of Public Health Central South University, changsha, China (People's Republic), 3Xiangya Hospital Central South University, Changsha, China (People's Republic), 4Massachusetts General Hospital, Harvard Medical School, Boston, 5University of Auckland, Auckland, New Zealand, 6University of Oxford, Oxford, 7Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic)

    Background/Purpose: Previous studies have reported that walking is associated with a lower risk of several metabolic diseases; however, evidence of its association with gout, a…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology